Keywords: Biomarkers, Preclinical, Targeted contrast agent
Motivation: Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that often metastasizes early. Early and accurate diagnosis is imperative for improving TNBC patient management and survival.
Goal(s): We aim to evaluate MT218, an MRI contrast agent targeting extradomain-B fibronectin in the tumor extracellular matrix, in more clinically relevant small animal models.
Approach: Using NSG mice bearing TNBC PDX xenografts, we performed MRI of tumors after administration of MT218 at doses significantly lower than the clinical dose.
Results: Both low doses of MT218 demonstrated significant tumor-specific enhancement and facilitated the delineation of tumor boundaries for effective MRI of TNBC.
Impact: We demonstrate that MT218 can effectively enhance patient-derived xenograft tumors of triple negative breast cancer, a clinically relevant tumor model, further supporting the clinical translation of MT218 for magnetic resonance molecular imaging of cancer.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords